← Back to Patent Explorer
US5569647A Expired / Lapsed US ⏱️ 0.0 years remaining

Angiopeptin cyclopeptide compounds

Assignee: Les Laboratoires Servier SAS
•
Filing: 1995-06-06
•
Granted: 1996-10-29
•
Expires: 2015-06-06
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The invention relates to a compound selected from those of formula (I) (SEQ ID NO:1): <IMAGE> (I) in which R1, R2, X1 and X2 are as defined in the description, useful as inhibitor of the proliferation component of vascular smooth muscle cells.

Inventors

  • 👤 Jean-Luc Fauchere
  • 👤 Christophe Thurieau
  • 👤 Jean-Paul Vilaine
  • 👤 Philip Janiak

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-23 12:58
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/575; C07K14/655; C07K14/6555; A; A61; A61P; A61P3/00; A61P3/08; A61P3/10; A61P35/00; A61P9/00; A61P9/10; A61P9/12; A61K; A61K38/00

Claims Analysis

Total Claims: 4
Claim 1
Independent Claim 105 words
A compound selected from those of formula (I): ##STR8## in which: R 1 represents a 3-(2-naphthyl)-D-alanine (D-Nal) residue, R 2 represents a threonine (Thr) residue, X 1 and X 2 are a glutamic acid residue (Glu) and a L-2,4-diaminobutyric acid residue (Dab), respectively which are connected by means of an amide bond and which confer on the ring so formed a number of atoms equal to 22, Tyr represents the L-tyrosine residue, D-Trp represents the D-tryptophan residue, Lys represents the L-lysine residue, and Val represents the L-valine residue, its enantiomers, diastereoisomers and epimers, as well as its addition salts with a pharmaceutically-acceptable acid or base.
Claim 2
Dependent Claim 105 words
A compound selected from those of formula (I): ##STR8## in which: R 1 represents a 3-(2-naphthyl)-D-alanine (D-Nal) residue, R 2 represents a threonine (Thr) residue, X 1 and X 2 are a glutamic acid residue (Glu) and a L-2,4-diaminobutyric acid residue (Dab), respectively which are connected by means of an amide bond and which confer on the ring so formed a number of atoms equal to 22, Tyr represents the L-tyrosine residue, D-Trp represents the D-tryptophan residue, Lys represents the L-lysine residue, and Val represents the L-valine residue, its enantiomers, diastereoisomers and epimers, as well as its addition salts with a pharmaceutically-acceptable acid or base.
Claim 3
Dependent Claim 82 words
A method for treating an animal or human living body afflicted with a disease requiring an inhibitor of the proliferation component of vascular smooth muscle cells resulting from atherosclerotic vascular lesions, vascular re-stenosis following bypass surgery, vascular dilation, and heart transplant, vascular alterations associated with arterial hypertension, proliferative diabetic retinopathy, breast, lung and prostate cancers, and psoriasis, comprising the step of administering to said living body an amount of a compound of claim 1 which is effective for alleviation of said disease.
Claim 4
Dependent Claim 40 words
A pharmaceutical composition useful as an inhibitor of the proliferation component of smooth muscle cells which contains as active ingredient an effective amount of a compound according to claim 1, in combination with one or more pharmaceutically-acceptable excipients or vehicles.

References Cited (Backward Citations)

US4603120A Cited
EP0180921A2 Cited
US4650787A Cited
US5147856A Cited
US5204326A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1999-10-29 2000-04-29 2000-10-29 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2003-10-29 2004-04-29 2004-10-29 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2007-10-29 2008-04-29 2008-10-29 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag